Expression of the Inhibitory Receptors on Lymphocytes T Cells After Lung Cancer Surgery.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-14

Study Completion Date

2019-02-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Postoperative pneumonia is one of the most common complications after lung cancer surgery and associated with a morbidity and mortality. Postoperative lymphopenia has been recently identified as one of risk factors for postoperative pneumonia. According to recent studies in polytrauma, cancer or septic shock, T cells dysfunction may be related to high expression of inhibitory receptors on lymphocytes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Meaning of Recovery After Lung Cancer Surgery

NCT05453812

Recovery Lung Cancer Surgery

UNKNOWN

Risk Factors for Postoperative Cough in Patients Undergoing Thoracoscopic Lung Resection

NCT06476249

Lung Cancer

RECRUITING

Chronic Pain After Thoracotomy, an Incidence Study in a Single Surgical Center

NCT00834769

Thoracotomy Chronic Pain

COMPLETED

Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study

NCT06743555

Non-Small Cell Lung Cancer Immunotherapy Neoadjuvant Therapy +2 more

NOT_YET_RECRUITING PHASE1

Effects of Nonintubated Thoracoscopic Lobectomy on Lung Protection

NCT03471884

Non-small Cell Lung Cancer Lung Function Decreased Tracheal Intubation Morbidity

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will investigate prospectively TIM-3, PD-1 and CTLA4 expression on lymphocytes T cells before and after lung cancer surgery. Patients ≥ 18 years with no history of immunosuppressive state will be included.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients undergoing lung cancer surgery

Patients undergoing lung cancer surgery will be included. Blood samples will be collected.

Group Type OTHER

Blood samples

Intervention Type BIOLOGICAL

Blood samples will be collected in patients undergoing lung cancer surgery:

* before lung cancer surgery,
* the next day lung cancer surgery,
* 3 days after lung cancer surgery. They will be treated in flow cytometry.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood samples

Blood samples will be collected in patients undergoing lung cancer surgery:

* before lung cancer surgery,
* the next day lung cancer surgery,
* 3 days after lung cancer surgery. They will be treated in flow cytometry.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient ≥ 18 years undergoing lung cancer surgery by thoracoscopy

Exclusion Criteria

* Patient under guardianship/curatorship
* Patient who received of radiotherapy or chemotherapy in the last 6 months
* Patient under immunosuppressive treatment or dose of corticoids over 10 mg/day prednisolone or equivalent
* Patient with history of malignant blood disease or auto-immune disease
* Patient suffering from HIV infection and
* Patients with pre-operative infection
* Patient with an empiric antibiotic therapy introduced at operating room

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No